Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis

Thyroid

Volumn 24, Issue 1, 2014, Pages 35-42

  Mcleod, Donald S A ^a,b   Cooper, David S ^c   Ladenson, Paul W ^c   Ain, Kenneth B ^d   Brierley, James D ^e   Fein, Henry G ^f   Haugen, Bryan R ^g   Jonklaas, Jacqueline ^h   Magner, James ⁱ   Ross, Douglas S ^j   Skarulis, Monica C ^k   Steward, David L ^l   Maxon, Harry R ^l   Sherman, Steven I ^m  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f SINAI HOSPITAL OF BALTIMORE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ GENZYME CORPORATION   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^m UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CERVICAL LYMPH NODE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; ONCOCYTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL;

AUTOANTIBODIES; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN;

EID: 84892177099     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0062     Document Type: Article

References (37)

1. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B 1997A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79:2414-2423
2. Lang BH, Chow SM, Lo CY, Law SC, Lam KY 2007 Staging systems for papillary thyroid carcinoma: A study of 2 tertiary referral centers. Ann Surg 246:114-121
3. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL 2012 Thyrotropin and thyroid cancer diagnosis: A systematic review and dose-response metaanalysis. J Clin Endocrinol Metab 97:2682-2692
4. Fiore E, Vitti P 2012 Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 97:1134-1145
5. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323
6. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242
7. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610-2615
8. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121-1127
9. Feldt-Rasmussen U, Rasmussen AK 2010 Autoimmunity in differentiated thyroid cancer: Significance and related clinical problems. Hormones (Athens) 9:109-117
10. Cunha LL, Ferreira RC, Marcello MA, Vassallo J, Ward LS 2011 Clinical and pathologic implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. J Thyroid Res 2011:387062
11. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR 3rd 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744
12. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR 3rd 1998 Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021
13. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129:622-627
14. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19:1043-1048
15. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2010 Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20:1423-1424
16. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2012 The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97:E878-E887
17. American Joint Committee on Cancer 2010 Thyroid. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC Cancer Staging Manual. Seventh edition. Springer, New York, pp 87-96
18. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809-814
19. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P 2009 Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: Thyroid autonomy may play a protective role. Endocr Relat Cancer 16:1251-1260
20. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H 2009 Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 71:434-439
21. Kim SS, Lee BJ, Lee JC, Song SH, Kim BH, Son SM, Kim IJ, Kim YK, Kang YH 2011 Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: A single-center experience. Endocrine 39:259-265
22. Jung E, Shon H 2011 Association between serum TSH level and papillary thyroid microcarcinoma in Korean euthyroid patients. Thyroid 21:A93 (Abstract
23. Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, Song KH, Kang MI, Cha BY, Lee KW, Son HY 2010 Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 20:885-891
24. Ahn D, Sohn JH, Kim JH, Shin CM, Jeon JH, Park JY 2013 Preoperative subclinical hypothyroidism in patients with papillary thyroid carcinoma. Am J Otolaryngol 34:312-219
25. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA 2011 Thyrotrophin receptor signaling dependence of Brafinduced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615-1620
26. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
27. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P 2010 Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: Analysis of 1060 cases. J Clin Endocrinol Metab 95:4197-4205
28. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
29. Morshed SA, Latif R, Davies TF 2009 Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150:519-529
30. Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY, Ringel MD 2011 Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 30:4307-4315
31. Kashima K, Yokoyama S, Noguchi S,Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Na-kayama I 1998 Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8:197-202
32. Huang BY, Hseuh C, Chao TC, Lin KJ, Lin JD 2011 Welldifferentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 22:144-149
33. Souza SL, Montalli Da Assumpçäo LV, Ward LS 2003 Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer. Thyroid 13:491-495
34. Kebebew E, Treseler PA, Ituarte PH, Clark OH 2001 Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 25:632-637
35. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, Hong SJ, Gong G, Shong YK 2009 Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 71:581-586
36. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H 1995 The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80:3421-3424
37. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP 1999 Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84:458-463